To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA)

Study Identifier
P13-518
CT.gov Identifier
NCT02028169
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Psoriatic Arthritis (PsA)
  • Other
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18 - 90 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Actively working, either full-time or part-time * Previous confirmed diagnosis of PsA by a rheumatologist * Patients for whom the physician has initiated PsA treatment with an Anti-TNF in accordance with Turkish Ministry of Health regulations and reimbursement criteria * Able to provide authorization to use and disclose their health related information
    Exclusion Criteria:
    * Patients with a history of an allergic reaction or significant sensitivity to anti-TNF agents * Patients with possible follow-up problems during the planned study period or patients who may not be compliant to treatment as evaluated by the investigator/treating physician * Patients participating in any clinical trial of an experimental drug 30 days prior to the baseline visit

    Protocol Summary

    This post marketing observational study is designed to provide the initial data on work impairment of PsA patients in Turkey, as well as changes in work impairment, life quality and clinical response during treatment with anti-TNF agents.

    Study Locations

    No locations found.